BioSpace News Archive

Neuros Medical, Inc. today announced that David Veino has been appointed President and Chief Executive Officer.

Ascentage Pharma (6855.HK) announced today that it has released the latest clinical data of its dual Bcl-2/Bcl-xL inhibitor, APG-1252 (pelcitoclax), combined with osimertinib for the treatment of patients with EGFR-mutant non-small cell lung cancer (NSCLC) in a Mini Oral at the 2023 European Society of Medical Oncology (ESMO) Congress.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received U.S. Food and Drug Administration (FDA) approval for the Aurora EV-ICD™ MRI SureScan™ (Extravascular Implantable Cardioverter-Defibrillator) and Epsila EV™ MRI SureScan™ defibrillation lead to treat dangerously fast heart rhythms that can lead to sudden cardiac arrest (SCA).

Enterome today announced updated, encouraging results from Phase 1/2 SPENCER trial of EO2401 in combination with nivolumab in adrenocortical carcinoma (ACC) and metastatic pheochromocytoma/paraganglioma (MPP), two forms of adrenal tumors.

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its Q3 2023 business and financial highlights before the opening of the market on October 26, 2023.

Avistone Biotechnology Co., Ltd. (“Avistone” or “the Company”) announced preliminary results of the Phase II KUNPENG study of Vebreltinib in Patients (Pts) with advanced Non-small cell lung cancer (NSCLC) Harboring MET (mesenchymal-epithelial transition factor) alterations (Poster# 1379P) at the European Society for Clinical Oncology (ESMO) Congress in Madrid, Spain.

iQure Pharma Inc. (iQure), a CNS company dedicated to the development of new epilepsy and pain management therapeutics, has completed the first closing of its latest round of funding.

Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today announced their participation at the 6th Clinical Trials on Alzheimer’s Disease (CTAD) occurring October 24-27, 2023 in Boston, MA.

Alkermes’ mission is to research, develop and commercialize important new medicines for patients suffering from complex medical conditions, including those who are often unfairly marginalized or stigmatized because of their illness.

Advanced Infusion Care, a division of AIS Healthcare, announced an agreement to conduct a joint study with Grifols, a leading global provider of essential plasma-derived and transfusion medicines, to observe the effects of subcutaneous immunoglobulin products on individuals living with primary immune deficiencies.